Cholangiocarcinoma clinical trials
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-05
What changed in the last 30 days
35 trials changed in the last 30 days: 2 stopped, 18 with notable changes, 15 with minor changes only.
- Stopped: Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 · Advanced Biliary Tract Cancer Trial terminated
- Notable: Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy · Advanced Hepatopancreabiliary Tumors (BLOCKED) Primary completion pushed from Oct 1, 2026 to May 1, 2027
- Minor: Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma Start date pushed from Oct 2026 to Nov 2026
- Notable: Targeted Navigation in Hepatocellular Carcinoma (HCC) Primary endpoint(s) modified
- Minor: TIKET · TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors Changed Registry marked status Unknown (sponsor has not verified the record since Jun 2024); last known: Recruiting
- Notable: BOLD-100 in Combination With FOLFOX With or Without Bevacizumab · Advanced, Solid Tumours Primary completion pushed from Jun 1, 2026 to Jul 1, 2027
- Notable: NAPOLI-2 · Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer Results posted: Oct 27, 2026
- Minor: FiREBOLT · LY4337713 · FAP-Positive Solid Tumors Enrollment increased: 241 → 340 participants
- Minor: RAINBOW · Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma Trial sites expanded: 18 → 21 locations
- Notable: BRAVE · Breath Research Narrow Validation for Gastrointestinal Cancer Detection Primary and study completion dates pushed to Feb 2, 2029
- Minor: IDHIRA · Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study Trial sites expanded: 16 → 19 locations
- Stopped: Trifluridine/Tipiracil + Oxaliplatin · Advanced or Metastatic Biliary Tract Cancer Recruitment suspended
- Notable: EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope Primary completion pushed from Dec 2026 to Dec 2027
- Minor: [18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma Start date changed from estimate of Nov 1, 2026 to Oct 8, 2026
- Minor: Biodistribution of an Imaging Tracer (68Ga-FAPi-46) · Solid Tumors or Hematologic Cancers Primary completion date changed from estimate of Sep 6, 2026 to Jun 23, 2026
- Minor: Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) Study completion pushed from Oct 1, 2026 to Oct 15, 2027
- Notable: Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome Primary and study completion pushed from Jul 1, 2026 to Jul 1, 2027
- Notable: SumMET · [225Ac]Ac-FL-261 · Solid Tumors Overexpressing c-MET Recruitment opened
- Notable: Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body · Advanced Solid Tumors Recruitment opened
- Minor: AVENTINE-1 · AVZO-1418 as a Single Agent and in Combination Therapy · Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) Trial sites expanded: 19 → 27 locations
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New sponsor entrants, last 90 days sponsors with their first trial in this area
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-11-02 | NCT07909031 CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Crescent Biopharma, Inc. new | Phase 1/2 |
| 2026-10-14 | NCT07873450 SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET | Full-Life Technologies UK Limited new | Phase 1/2 |
| 2026-09-25 | NCT07841574 HAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICC | Lianghe Lu new | Phase 2 |
| 2026-09-10 | NCT07812805 SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors | SK Life Science, Inc. new | Phase 1 |
| 2026-09-01 | NCT07796997 GI-06: The Impact of Perioperative Hydrocortisone on Patients Undergoing Partial… | University of Illinois at Chicago new | Phase 1 |
| 2026-08-26 | NCT07786766 Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2… | Haitao Zhao, MD new | Phase 2 |
| 2026-08-24 | NCT07780838 Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or… | Ohio State University Comprehensive Cancer Center new | Phase 2 |
| 2026-08-14 | NCT07765433 Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the… | ECOG-ACRIN Cancer Research Group new | Phase 2/3 |
Active trials by phase
| Early Phase 1 | 6 | |
| Phase 1 | 56 | |
| Phase 1/2 | 50 | |
| Phase 2 | 210 | |
| Phase 2/3 | 13 | |
| Phase 3 | 26 | |
| Phase 4 | 10 |
Not charted: 181 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Top sponsors by active trials in this area
National Cancer Institute (NCI) (17) · Fudan University (16) · Shanghai Zhongshan Hospital (14) · AstraZeneca (11) · Tianjin Medical University Cancer Institute and Hospital (11) · M.D. Anderson Cancer Center (10) · Peking Union Medical College Hospital (10) · Mayo Clinic (8) · Second Affiliated Hospital, Zhejiang University, School of Medicine (8) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (6)
Get alerts when Cholangiocarcinoma trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.